Global Cancer Biomarker Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Cancer Biomarker Revenue
• 1.4 Market by Type
  • 1.4.1 Global Cancer Biomarker Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Protein Biomarker
  • 1.4.3 Genetic Biomarker
• 1.5 Market by Application
  • 1.5.1 Global Cancer Biomarker Market Share by Application: 2020 VS 2026
  • 1.5.2 Diagnostics
  • 1.5.3 Research
  • 1.5.4 Prognostics
  • 1.5.5 Risk Assessment
  • 1.5.6 Other Applications
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Cancer Biomarker Market Perspective (2015-2026)
• 2.2 Global Cancer Biomarker Growth Trends by Regions
  • 2.2.1 Cancer Biomarker Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Cancer Biomarker Historic Market Share by Regions (2015-2020)
  • 2.2.3 Cancer Biomarker Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Cancer Biomarker Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Cancer Biomarker Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Cancer Biomarker Players by Market Size
  • 3.1.1 Global Top Cancer Biomarker Players by Revenue (2015-2020)
  • 3.1.2 Global Cancer Biomarker Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Cancer Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Cancer Biomarker Market Concentration Ratio
  • 3.2.1 Global Cancer Biomarker Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Cancer Biomarker Revenue in 2019
• 3.3 Cancer Biomarker Key Players Head office and Area Served
• 3.4 Key Players Cancer Biomarker Product Solution and Service
• 3.5 Date of Enter into Cancer Biomarker Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Cancer Biomarker Historic Market Size by Type (2015-2020)
• 4.2 Global Cancer Biomarker Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Cancer Biomarker Market Size by Application (2015-2020)
• 5.2 Global Cancer Biomarker Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Cancer Biomarker Market Size (2015-2020)
• 6.2 Cancer Biomarker Key Players in North America (2019-2020)
• 6.3 North America Cancer Biomarker Market Size by Type (2015-2020)
• 6.4 North America Cancer Biomarker Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Cancer Biomarker Market Size (2015-2020)
• 7.2 Cancer Biomarker Key Players in Europe (2019-2020)
• 7.3 Europe Cancer Biomarker Market Size by Type (2015-2020)
• 7.4 Europe Cancer Biomarker Market Size by Application (2015-2020)

8 China

• 8.1 China Cancer Biomarker Market Size (2015-2020)
• 8.2 Cancer Biomarker Key Players in China (2019-2020)
• 8.3 China Cancer Biomarker Market Size by Type (2015-2020)
• 8.4 China Cancer Biomarker Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Cancer Biomarker Market Size (2015-2020)
• 9.2 Cancer Biomarker Key Players in Japan (2019-2020)
• 9.3 Japan Cancer Biomarker Market Size by Type (2015-2020)
• 9.4 Japan Cancer Biomarker Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Cancer Biomarker Market Size (2015-2020)
• 10.2 Cancer Biomarker Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Cancer Biomarker Market Size by Type (2015-2020)
• 10.4 Southeast Asia Cancer Biomarker Market Size by Application (2015-2020)

11 India

• 11.1 India Cancer Biomarker Market Size (2015-2020)
• 11.2 Cancer Biomarker Key Players in India (2019-2020)
• 11.3 India Cancer Biomarker Market Size by Type (2015-2020)
• 11.4 India Cancer Biomarker Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Cancer Biomarker Market Size (2015-2020)
• 12.2 Cancer Biomarker Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Cancer Biomarker Market Size by Type (2015-2020)
• 12.4 Central & South America Cancer Biomarker Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Thermo Fisher Scientific
  • 13.1.1 Thermo Fisher Scientific Company Details
  • 13.1.2 Thermo Fisher Scientific Business Overview
  • 13.1.3 Thermo Fisher Scientific Cancer Biomarker Introduction
  • 13.1.4 Thermo Fisher Scientific Revenue in Cancer Biomarker Business (2015-2020))
  • 13.1.5 Thermo Fisher Scientific Recent Development
• 13.2 Bio-Rad Laboratories
  • 13.2.1 Bio-Rad Laboratories Company Details
  • 13.2.2 Bio-Rad Laboratories Business Overview
  • 13.2.3 Bio-Rad Laboratories Cancer Biomarker Introduction
  • 13.2.4 Bio-Rad Laboratories Revenue in Cancer Biomarker Business (2015-2020)
  • 13.2.5 Bio-Rad Laboratories Recent Development
• 13.3 Roche Diagnostics
  • 13.3.1 Roche Diagnostics Company Details
  • 13.3.2 Roche Diagnostics Business Overview
  • 13.3.3 Roche Diagnostics Cancer Biomarker Introduction
  • 13.3.4 Roche Diagnostics Revenue in Cancer Biomarker Business (2015-2020)
  • 13.3.5 Roche Diagnostics Recent Development
• 13.4 Qiagen
  • 13.4.1 Qiagen Company Details
  • 13.4.2 Qiagen Business Overview
  • 13.4.3 Qiagen Cancer Biomarker Introduction
  • 13.4.4 Qiagen Revenue in Cancer Biomarker Business (2015-2020)
  • 13.4.5 Qiagen Recent Development
• 13.5 Illumina
  • 13.5.1 Illumina Company Details
  • 13.5.2 Illumina Business Overview
  • 13.5.3 Illumina Cancer Biomarker Introduction
  • 13.5.4 Illumina Revenue in Cancer Biomarker Business (2015-2020)
  • 13.5.5 Illumina Recent Development
• 13.6 GE Healthcare
  • 13.6.1 GE Healthcare Company Details
  • 13.6.2 GE Healthcare Business Overview
  • 13.6.3 GE Healthcare Cancer Biomarker Introduction
  • 13.6.4 GE Healthcare Revenue in Cancer Biomarker Business (2015-2020)
  • 13.6.5 GE Healthcare Recent Development
• 13.7 Agilent Technologies
  • 13.7.1 Agilent Technologies Company Details
  • 13.7.2 Agilent Technologies Business Overview
  • 13.7.3 Agilent Technologies Cancer Biomarker Introduction
  • 13.7.4 Agilent Technologies Revenue in Cancer Biomarker Business (2015-2020)
  • 13.7.5 Agilent Technologies Recent Development
• 13.8 Biomérieux SA
  • 13.8.1 Biomérieux SA Company Details
  • 13.8.2 Biomérieux SA Business Overview
  • 13.8.3 Biomérieux SA Cancer Biomarker Introduction
  • 13.8.4 Biomérieux SA Revenue in Cancer Biomarker Business (2015-2020)
  • 13.8.5 Biomérieux SA Recent Development
• 13.9 Merck & Co.
  • 13.9.1 Merck & Co. Company Details
  • 13.9.2 Merck & Co. Business Overview
  • 13.9.3 Merck & Co. Cancer Biomarker Introduction
  • 13.9.4 Merck & Co. Revenue in Cancer Biomarker Business (2015-2020)
  • 13.9.5 Merck & Co. Recent Development
• 13.10 Abbott Laboratories
  • 13.10.1 Abbott Laboratories Company Details
  • 13.10.2 Abbott Laboratories Business Overview
  • 13.10.3 Abbott Laboratories Cancer Biomarker Introduction
  • 13.10.4 Abbott Laboratories Revenue in Cancer Biomarker Business (2015-2020)
  • 13.10.5 Abbott Laboratories Recent Development
• 13.11 Becton, Dickinson and Company
  • 10.11.1 Becton, Dickinson and Company Company Details
  • 10.11.2 Becton, Dickinson and Company Business Overview
  • 10.11.3 Becton, Dickinson and Company Cancer Biomarker Introduction
  • 10.11.4 Becton, Dickinson and Company Revenue in Cancer Biomarker Business (2015-2020)
  • 10.11.5 Becton, Dickinson and Company Recent Development
• 13.12 Danaher Corporation
  • 10.12.1 Danaher Corporation Company Details
  • 10.12.2 Danaher Corporation Business Overview
  • 10.12.3 Danaher Corporation Cancer Biomarker Introduction
  • 10.12.4 Danaher Corporation Revenue in Cancer Biomarker Business (2015-2020)
  • 10.12.5 Danaher Corporation Recent Development
• 13.13 Myriad Genetics
  • 10.13.1 Myriad Genetics Company Details
  • 10.13.2 Myriad Genetics Business Overview
  • 10.13.3 Myriad Genetics Cancer Biomarker Introduction
  • 10.13.4 Myriad Genetics Revenue in Cancer Biomarker Business (2015-2020)
  • 10.13.5 Myriad Genetics Recent Development
• 13.14 Sysmex Corporation
  • 10.14.1 Sysmex Corporation Company Details
  • 10.14.2 Sysmex Corporation Business Overview
  • 10.14.3 Sysmex Corporation Cancer Biomarker Introduction
  • 10.14.4 Sysmex Corporation Revenue in Cancer Biomarker Business (2015-2020)
  • 10.14.5 Sysmex Corporation Recent Development
• 13.15 Hologic
  • 10.15.1 Hologic Company Details
  • 10.15.2 Hologic Business Overview
  • 10.15.3 Hologic Cancer Biomarker Introduction
  • 10.15.4 Hologic Revenue in Cancer Biomarker Business (2015-2020)
  • 10.15.5 Hologic Recent Development
• 13.16 Quest Diagnostics
  • 10.16.1 Quest Diagnostics Company Details
  • 10.16.2 Quest Diagnostics Business Overview
  • 10.16.3 Quest Diagnostics Cancer Biomarker Introduction
  • 10.16.4 Quest Diagnostics Revenue in Cancer Biomarker Business (2015-2020)
  • 10.16.5 Quest Diagnostics Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer